Pioglitazone and clarithromycin combined with metronomic chemotherapy vs. nivolumab in patients with advanced non-small-cell lung cancer: Outcomes from a randomized phase II trial (ModuLung) | Anticancerfund
Independent research fund focusing on cancer treatments

Pioglitazone and clarithromycin combined with metronomic chemotherapy vs. nivolumab in patients with advanced non-small-cell lung cancer: Outcomes from a randomized phase II trial (ModuLung)

POSTER
Presented at ESMO 2019

Read more on the Modulung trial here

PDF icon esmo_2019_poster_modulung_final.pdf